Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spectranetics search warrant

This article was originally published in The Gray Sheet

Executive Summary

Maker of CVX-300 excimer laser systems is jointly served by FDA and U.S. Immigration and Customs Enforcement with a search warrant Sept. 4, issued by the U.S. District Court, District of Colorado. The warrant requests information and correspondence related to the promotion, testing and marketing of certain products for the treatment of in-stent restenosis and related payments made to medical personnel and one institution; the promotion, testing, delivery and marketing of catheter guidewires and balloon catheters manufactured by third-parties located outside of the U.S.; two post-market studies completed from 2002-2005 and payments tied to those studies; and compensation packages for some Spectranetics personnel. The firm says it is cooperating fully and expects business to continue as usual. The firm's stock price fell 47% on Sept. 4 to $4.73

You may also be interested in...



Spectranetics settlement

Excimer laser system maker Spectranetics will pay $4.9 million in civil damages plus a $100,000 forfeiture to resolve claims that it illegally imported and sold unapproved medical devices from overseas manufacturers, failed to meet clinical trial reporting requirements and promoted certain products for unapproved uses, the Justice Department announced Dec. 29. In addition to the civil settlement, the firm entered into a non-prosecution agreement and corporate integrity agreement to resolve the matter. According to the non-prosecution agreement, Spectranetics accepts responsibility for its conduct and will not be criminally prosecuted. As part of the integrity agreement, the firm's clinical trial records will be audited by an independent review organization "to insure compliance with FDA rules - including reporting of adverse events," HHS Inspector General Daniel Levinson said. FDA and U.S. Immigration and Customs Enforcement had served Spectranetics with a search warrant requesting information related to the matter in September 2008 (1"The Gray Sheet" Sept. 15, 2008)

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel